Ticagrelor (CAS 274693-27-5)/API

Ticagrelor (CAS 274693-27-5) is a high-purity pharmaceutical API classified as a reversible P2Y12 antagonist, featuring a cyclopentyltriazolopyrimidine molecular structure engineered for rapid antiplatelet action. Unlike irreversible P2Y12 inhibitors, it binds reversibly to the P2Y12 receptor on platelets, blocking ADP-mediated platelet aggregation without permanent receptor modification—enabling faster recovery of platelet function when treatment is discontinued. This premium API exhibits quick onset (30 minutes post-oral administration) and consistent bioavailability, making it suitable for acute and long-term cardiovascular protection.

It caters to the core needs of cardiovascular drug manufacturers, antiplatelet therapy developers, and clinical supply chains. Widely applied in developing treatments for acute coronary syndrome (ACS), myocardial infarction, and ischemic stroke, it aligns with the demand for flexible, well-tolerated antithrombotic therapies. Produced under strict GMP standards, each batch undergoes rigorous purity and potency testing to meet international pharmacopoeia requirements, ensuring reliability for clinical use. For businesses prioritizing evidence-based cardiovascular protection solutions, this Ticagrelor API serves as a critical raw material for advancing antiplatelet medication development.